[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540698":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":37,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":11,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Prostate cancer patients with PSMA PET",null,"Inclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer.",[13],{"name":14,"affiliation":5,"role":15},"Wolfgang P Fendler, M.D.","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+492017232032","redcap@ikim.nrw",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University Hospital Essen","RECRUITING","Essen","45147","Germany","DE",{"type":30,"coordinates":31},"Point",[32,33],7.01228,51.45657,{"lat":33,"lon":32},[36],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540698",false,"NCT06320223","PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer","PROMISE-PET","MALE","18 Years",{"count":48,"type":49},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Background:\n\nPROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.\n\nNeed:\n\nImproved prognostication across various stages of prostate cancer is needed for management guidance and study design.\n\nAim:\n\n1. To assess the prognostic value of PSMA PET\n2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages\n\nInclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer",[54,55,56,57],"Prostate Cancer","PET\u002FCT","Survivorship","PSMA",[54,55,56,57,59,60,61,62],"Nuclear Medicine","Imaging","Oncology","Urology","2024-03-15",{"date":65,"type":66},"2024-03-20","ACTUAL",{"date":68,"type":66},"2024-03-05",{"date":70,"type":49},"2035-03-05",{"name":5,"class":6},1]